What is Catheter Precision?
Catheter Precision operates at the intersection of medical technology and clinical electrophysiology, focusing on the development of sophisticated tools designed to treat cardiac arrhythmias. The company's product portfolio, which includes the eIFU, Vivo, and LockeT systems, is engineered to provide healthcare professionals with greater precision and efficiency during complex cardiac procedures. By addressing the critical needs of medical providers, Catheter Precision has established itself as a pivotal player in the effort to improve long-term patient outcomes and streamline hospital workflows in the cardiovascular space.
How much funding has Catheter Precision raised?
Catheter Precision has raised a total of $1.6M across 2 funding rounds:
Debt
$150K
Stock/Share Issuance
$1.5M
Debt (2020): $150K with participation from PPP
Stock/Share Issuance (2025): $1.5M, investors not publicly disclosed
Key Investors in Catheter Precision
PPP
Public-Private Partnership
Undisclosed Investor
An undisclosed institutional backer participating in the latest round of strategic financing to support long-term enterprise development.
Undisclosed Investor
An undisclosed investor focused on high-growth medical technology firms and healthcare innovation.
What's next for Catheter Precision?
With the recent infusion of capital, Catheter Precision is poised to scale its operational capabilities and expand the market reach of its core electrophysiology platforms. The strategic focus will likely shift toward enhancing research and development initiatives to further refine its existing product suite while exploring new avenues for clinical application. As the company transitions into this next phase of growth, the emphasis remains on maintaining high standards of medical efficacy and securing a larger footprint within the global cardiac care market, ensuring that their innovative solutions reach a broader demographic of patients suffering from rhythm disorders.
See full Catheter Precision company page
